14 April 2026 Zurich, Switzerland-based CRO InSphero, the global leader in 3D cell-based assays and organ-on-chip systems, announces the commercial launch of the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput screening solution for early assessment of gastrointestinal (GI) liabilities in drug discovery. Despite efforts to flag GI toxicity risk early in the drug discovery process, DIGIT remains among the most common cau